|
Business Combinations - Additional Information (Detail) (USD $)
|
3 Months Ended | 12 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 30, 2013
|
Sep. 28, 2013
|
Sep. 29, 2012
|
Sep. 24, 2011
|
Jan. 03, 2013
|
Sep. 28, 2013
Property, Plant and Equipment [Member]
|
Sep. 28, 2013
Land and Buildings [Member]
|
Dec. 31, 2012
Chindex Medical Limited [Member]
|
May 31, 2013
SenoRx, Inc [Member]
|
Jun. 01, 2011
TCT International Co., Ltd. [Member]
Y
|
Sep. 28, 2013
TCT International Co., Ltd. [Member]
|
Sep. 29, 2012
TCT International Co., Ltd. [Member]
|
Dec. 24, 2011
TCT International Co., Ltd. [Member]
|
Sep. 28, 2013
TCT International Co., Ltd. [Member]
|
Sep. 29, 2012
TCT International Co., Ltd. [Member]
Y
|
Sep. 24, 2011
TCT International Co., Ltd. [Member]
|
Sep. 28, 2013
Trade Names [Member]
TCT International Co., Ltd. [Member]
|
Sep. 28, 2013
Customer Relationships [Member]
TCT International Co., Ltd. [Member]
|
Sep. 28, 2013
Business Licenses [Member]
TCT International Co., Ltd. [Member]
|
Aug. 01, 2012
Gen-Probe Incorporated [Member]
|
Jun. 29, 2013
Gen-Probe Incorporated [Member]
|
Dec. 29, 2012
Gen-Probe Incorporated [Member]
|
Sep. 28, 2013
Gen-Probe Incorporated [Member]
|
Sep. 29, 2012
Gen-Probe Incorporated [Member]
|
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Minimum [Member]
|
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Maximum [Member]
|
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Developed Technology [Member]
|
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Customer Contract [Member]
|
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Trade Names [Member]
|
Jan. 06, 2011
Interlace Medical, Inc [Member]
|
Mar. 30, 2013
Interlace Medical, Inc [Member]
|
Mar. 24, 2012
Interlace Medical, Inc [Member]
|
Sep. 28, 2013
Interlace Medical, Inc [Member]
|
Sep. 24, 2011
Interlace Medical, Inc [Member]
|
Sep. 29, 2012
Interlace Medical, Inc [Member]
|
Sep. 28, 2013
Interlace Medical, Inc [Member]
First measurement period [Member]
|
Sep. 29, 2012
Interlace Medical, Inc [Member]
First measurement period [Member]
|
Mar. 30, 2013
Interlace Medical, Inc [Member]
Second measurement period [Member]
|
Sep. 28, 2013
Interlace Medical, Inc [Member]
Developed Technology [Member]
|
Sep. 28, 2013
Interlace Medical, Inc [Member]
Trade Names [Member]
|
Sep. 29, 2012
Beijing Healthcome Technology Company, Ltd. [Member]
|
Sep. 24, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
|
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
|
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Minimum [Member]
|
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Maximum [Member]
|
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Developed Technology [Member]
|
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Trade Names [Member]
|
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
In-process Research and Development [Member]
|
|
| Business Acquisition [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net purchase price | $ 4,400,000 | $ 2,400,000 | $ 148,400,000 | $ 3,972,176,000 | $ 213,398,000 | |||||||||||||||||||||||||||||||||||||||||||
| Cash paid per share | $ 82.75 | |||||||||||||||||||||||||||||||||||||||||||||||
| Amount paid to shareholders | 3,800,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Amount paid to equity award holders | 169,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Net debt obtained by the Company to finance the acquisition | 3,480,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Direct transaction costs incurred | 34,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Remaining fair value of stock options assumed to be recognized as compensation expense | 23,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Vesting period | 3 years 6 months | |||||||||||||||||||||||||||||||||||||||||||||||
| Risk free interest rate | 0.50% | 0.70% | 1.00% | 0.41% | ||||||||||||||||||||||||||||||||||||||||||||
| Expected volatility | 39.90% | |||||||||||||||||||||||||||||||||||||||||||||||
| Expected life | 3 years 7 months 6 days | |||||||||||||||||||||||||||||||||||||||||||||||
| Dividend yield, rate | 0.00% | |||||||||||||||||||||||||||||||||||||||||||||||
| Weighted average fair value of stock options, per share | $ 7.07 | |||||||||||||||||||||||||||||||||||||||||||||||
| Increase in developed technology | 135,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Reduction in process research and development | 110,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Adjustment to valuation of intangibles | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Agreement to sell LIFECODES business to Immucor | 85,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Contingent payment of an additional amount based on future revenue results | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Gain on the sale of LIFECODES business | 900,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Assets held-for-sale | 2,800,000 | 2,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Discount rate used for cash flow projections | 12.50% | 10.00% | 12.00% | 15.60% | 12.70% | 27.00% | 30.00% | |||||||||||||||||||||||||||||||||||||||||
| In-process research and development | 117,000,000 | 117,000,000 | 227,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
| In-process research and development, value | 93,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Total cost of completion of IPR&D projects | 49,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Discount rate | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||
| Expected number of years for project completion | 4 years | |||||||||||||||||||||||||||||||||||||||||||||||
| Finite-lived intangible assets, estimated useful life, years | 13 years 4 months 24 days | 13 years | 11 years | 15 years | 13 years | 13 years | 7 years | |||||||||||||||||||||||||||||||||||||||||
| Fair value adjustment to increase the carrying amount | 107,900,000 | 70,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Revenue earned by Gen-Probe post-acquisition | 89,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Pre-tax income (loss) from Gen-Probe post-acquisition | 47,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition of equity interest, percentage | 100.00% | 100.00% | 100.00% | |||||||||||||||||||||||||||||||||||||||||||||
| Cash portion of purchase price | 135,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Cash paid | 6,273,000 | 100,000,000 | 900,000 | 3,967,866,000 | 126,798,000 | |||||||||||||||||||||||||||||||||||||||||||
| Deferred payment | 1,655,000 | 47,258,000 | 35,000,000 | 47,500,000 | 47,500,000 | |||||||||||||||||||||||||||||||||||||||||||
| Estimated working capital adjustment | 13,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Deferred payment, period deferred (Years) | 1 | |||||||||||||||||||||||||||||||||||||||||||||||
| Payments of Working Capital | 8,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Number of annual contingent payments | 2 | |||||||||||||||||||||||||||||||||||||||||||||||
| Maximum contingent earn-out payment | 200,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Compensation expense | 80,000,000 | 75,500,000 | 17,600,000 | |||||||||||||||||||||||||||||||||||||||||||||
| Contingent consideration payments | 42,958,000 | 51,680,000 | 4,294,000 | 87,400,000 | 54,000,000 | 31,700,000 | 93,800,000 | 51,800,000 | ||||||||||||||||||||||||||||||||||||||||
| Accrued contingent consideration | 31,700,000 | 31,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Finite-lived intangible assets, weighted average useful life, years | 12 years | 12 years 8 months 12 days | 10 years | |||||||||||||||||||||||||||||||||||||||||||||
| Maximum additional contingent payment | 225,000,000 | 7,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Contingent consideration arrangements recorded as compensation expense | 80,010,000 | 81,031,000 | 20,002,000 | 80,010,000 | 75,459,000 | 17,581,000 | 2,100,000 | 5,600,000 | 300,000 | |||||||||||||||||||||||||||||||||||||||
| Contingent consideration liability, fair value | 86,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Contingent consideration obligation, fair value | 11,300,000 | 41,800,000 | 86,900,000 | |||||||||||||||||||||||||||||||||||||||||||||
| Contingent consideration - fair value adjustments | 11,310,000 | 38,466,000 | (8,016,000) | 6,300,000 | ||||||||||||||||||||||||||||||||||||||||||||
| Payment of contingent consideration classified in the financing section of the statement of cash flows | 39,000,000 | 47,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| Cash portion of purchase price | 8,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| Finite-lived intangible assets, weighted average useful life, years | 3,300,000 | 200,000 | 900,000 | |||||||||||||||||||||||||||||||||||||||||||||
| The excess of the purchase price over the fair value recorded to goodwill | $ 2,814,528,000 | $ 3,942,779,000 | $ 75,161,000 | $ 1,641,020,000 | $ 88,081,000 | $ 6,400,000 | ||||||||||||||||||||||||||||||||||||||||||